Anthracosis

Summary

Anthracosis (MONDO:0006654) is a disease and 1 clinical trial. Top therapeutic interventions include pirfenidone. A subtype of pneumoconiosis — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Clinical trials: 1

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	anthracosis
Mondo ID	MONDO:0006654
EFO	EFO:1000814
MeSH	D055008
DOID	DOID:10327
ICD-10-CM	J60
NCIT	C34390
SNOMED CT	29422001
UMLS	C0003165
MedGen	8107
GARD	0024454
MedDRA	10073051
Is cancer (heuristic)	no

Also known as: coal dust pneumoconiosis · coal miner’s pneumoconiosis · coal workers’ pneumoconiosis · pneumoconiosis from coal dust

Disease family

This is a subtype of pneumoconiosis. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by body system or component › respiratory system disorder › lower respiratory tract disorder › lung disorder › interstitial lung disease › pneumoconiosis › anthracosis

Related subtypes (13): mixed mineral dust pneumoconiosis, baritosis, pneumoconiosis due to talc, slate pneumoconiosis, Caplan syndrome, silicosis, anthracosilicosis, byssinosis, pulmonary hemosiderosis, chronic beryllium disease, asbestosis, mixed dust pneumoconiosis, graphite pneumoconiosis

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 1.

Phase distribution (across all retrieved trials)

Phase	Trials
PHASE2	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT04461587	PHASE2	COMPLETED	Examination of Pirfenidone (Esbriet®) Therapy in Coal Workers’ Pneumoconiosis With Pulmonary Fibrosis

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
PIRFENIDONE	4	1